Roche AG is planning early 2016 regulatory filings to seek approvals for ocrelizumab, a twice-yearly injectable multiple sclerosis (MS) therapy, after two phase III studies showed that it significantly reduced relapses and disability progression vs. Rebif (beta interferon 1a, EMD Serono Inc. and Pfizer Inc.) for people with relapsing MS, the most common form of the disease.